|
|
||||||||
CUTTING EDGE |


*
Department of Dermatology, Medical Faculty Charité, Humboldt University, Berlin, Germany; and
Institute for Organic Chemistry, University of Tübingen, Tübingen, Germany
TCR antagonists are altered T cell epitopes that specifically inactivate T cells. Commonly, they are derived from agonists by amino acid side chain replacement at positions accessible to the TCR. In this paper we report for the first time that a main chain N-hydroxylation, which is not exposed at the surface of the MHC peptide complex, renders an agonist into an antagonist. These mimotopes are a new, yet undescribed class of TCR antagonists. The antagonists are about 100 times more potent than an unrelated peptide that competes for binding to the MHC molecule. The novel main chain modification enhances biostability and maintains side chain constitution and thus opens new prospects for the use of TCR antagonists in the treatment of pathological immune reactions.
This article has been cited by other articles:
![]() |
M. Garcia-Peydro, A. Paradela, J. P. Albar, and J. A. L. d. Castro Antagonism of Direct Alloreactivity of an HLA-B27-Specific CTL Clone by Altered Peptide Ligands of Its Natural Epitope J. Immunol., November 15, 2000; 165(10): 5680 - 5685. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hin, A. Bianco, C. Zabel, G. Jung, and P. Walden Mimetics of a T Cell Epitope Based on Poly-N-acylated Amine Backbone Structures Induce T Cells in Vitro and in Vivo J. Biol. Chem., December 21, 2001; 276(52): 48790 - 48796. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |